Live tape
Top 8, mentions 7d28,448NVDA13,484 mentions▲ +0.04ANT4,066 mentions▲ +0.07GOOGL2,885 mentions▲ +0.04SPY2,239 mentions▲ +0.05QQQ1,768 mentions▲ +0.03SPCX1,536 mentions▲ +0.07AMD1,330 mentions▲ +0.06AAPL1,140 mentions▲ +0.04

Equity

ATHA

Athira Pharma (ATHA)

ATHA price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Have Athira Pharma (ATHA) insiders bought or sold shares recently?

ATHA's newest Form 4 filing is dated 2 January 2026: none in the last 90 days.

Form 4

Have Athira Pharma (ATHA) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
02 Jan 2026Litton Mark JamesPresident and CEOSell2,58618K USD
02 Jan 2026San Martin JavierCHIEF MEDICAL OFFICERSell1,64411K USD
02 Jan 2026CHURCH KEVINCHIEF SCIENTIFIC OFFICERSell8766K USD
02 Jan 2026Worthington MarkGeneral Counsel and CCOSell8766K USD
02 Jan 2026Renninger RobertChief Financial OfficerSell2972K USD
Sold5 open-market sales6,279$43K
8 other filings: grants, exercises, tax withholding and transfers, not trades
Have Athira Pharma (ATHA) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
31 Dec 2025Litton Mark JamesPresident and CEOOption exercise10,834
31 Dec 2025San Martin JavierCHIEF MEDICAL OFFICEROption exercise4,667
31 Dec 2025CHURCH KEVINCHIEF SCIENTIFIC OFFICEROption exercise3,667
31 Dec 2025Worthington MarkGeneral Counsel and CCOOption exercise3,667
31 Dec 2025Renninger RobertChief Financial OfficerOption exercise1,236
23 Dec 2025PERCEPTIVE ADVISORS LLCDirectorAward1,319,0268.4M USD
18 Nov 2025CHURCH KEVINCHIEF SCIENTIFIC OFFICERAward1,0002K USD
18 Nov 2025Renninger RobertChief Financial OfficerAward1,0002K USD

Which funds hold Athira Pharma (ATHA)?

4 of the 45 institutional funds we track reported a Athira Pharma position for the quarter ended 30 Sep 2026 — a combined 661K USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Athira Pharma (ATHA)?
FundPositionSharesValueShares q/q
Citadel AdvisorsAdded86,282308K USD+762.7%
Renaissance TechnologiesTrimmed56,966203K USD−26.4%
Millennium ManagementHeld (±25%)28,620102K USD−11.8%
Two Sigma InvestmentsHeld (±25%)13,27647K USD

Have members of Congress traded Athira Pharma (ATHA)?

The most recent congressional trade disclosed in Athira Pharma is a purchase by Sara Jacobs (house, CA), dated 12 Dec 2022.

STOCK Act disclosures

Have members of Congress traded Athira Pharma (ATHA)?
TradedMemberTypeAmountFiled after
12 Dec 2022Sara Jacobshouse · Democrat–CAPurchase1K USD–15K USD39 days
08 Nov 2022Sara Jacobshouse · Democrat–CASale1K USD–15K USD34 days
18 Jul 2022Sara Jacobshouse · Democrat–CAPurchase1K USD–15K USD53 days

What do people ask about Athira Pharma (ATHA)?

From live data
Have Athira Pharma insiders bought or sold shares recently?

No Athira Pharma insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 2 Jan 2026 (SEC Form 4). See Insiders

Which funds own Athira Pharma?4 of 45

4 of the 45 funds we track reported a Athira Pharma position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, Renaissance Technologies and Millennium Management. See Funds

Have members of Congress traded Athira Pharma?3 trades

Yes. 3 trades in Athira Pharma appear in the congressional disclosures we hold; the latest is a purchase by Sara Jacobs (House, CA) dated 12 Dec 2022, filed 20 Jan 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. TradingViewthe price chart widget, drawn by TradingView from their own data
  2. SEC EDGARForm 4 filings (insider transactions)
  3. SEC EDGAR13F filings
  4. Wikimedia CommonsPortraits via Wikimedia Commons. Sara Jacobs: Kristie Baxter, Public domain.
  5. House disclosuresU.S. House of Representatives financial disclosures
  6. Company websiteAbout text: the company's own website, summarised in our own words